4-HO-DiPT
4-HO-DiPT, also known as 4-hydroxy-N,''N-diisopropyltryptamine or as iprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin. It is taken orally. The drug has an unusually fast onset, short duration, and narrow dose range. Among orally administered psychedelics, it is one of the shortest-acting compounds known.
It acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. Unlike many other psychedelic tryptamines, the drug appears to have far lower potency as an agonist of the serotonin 5-HT2C receptor relative to the serotonin 5-HT2A receptor. It is a derivative of DiPT, a higher homologue of psilocin and 4-HO-DET, and a skeletal isomer of 4-HO-DPT.
4-HO-DiPT was first described in the scientific literature by 1977. It was later described in greater detail by Alexander Shulgin in his 1997 book TiHKAL''. The drug was encountered as a novel designer drug by 2005. In the 2020s, a prodrug of 4-HO-DiPT known as luvesilocin was developed and is in clinical trials for the treatment of psychiatric disorders such as postpartum depression.
Use and effects
In his book TiHKAL and other publications, Alexander Shulgin reported that 4-HO-DiPT had a dose range of 15 to 20mg orally and a duration of 2 to 3hours. However, a wider dose range of 3 to 30mg or more orally has also been reported. Shulgin has stated that 4-HO-DiPT has an especially steep dose–response curve and narrow dose range, with doses below 10mg producing few to no effects and doses of more than 20mg having not been tested due to the intensity of its effects. He personally found that a 20mg dose produced an intense plus-three experience on the Shulgin Rating Scale that "flirted with" the magical plus-four transcendental peak experience. The drug's onset of action is 15 to 20minutes and peak effects occur after 20 to 30minutes. Shulgin has stated that he "truly doubt that there is another psychedelic drug, anywhere, that can match for speed, for intensity, for brevity, and to dose, at least one that is active orally." However, ASR-3001, a more recent psychedelic, may be slightly faster than 4-HO-DiPT.The effects of 4-HO-DiPT have been reported to include introspective changes, insights and realizations, mild object distortion, slight color effects, rainbow halos around objects, very little in the way of closed-eye visuals, little in terms of psychedelic visuals or sensory changes in general, mild stimulation, mild elation, light tension, orgasmic enhancement, and powerful religious-esque experiences. Other effects included sensations of muscle loosening, leg tremors, chill-like sensations, and vague body malaise. Shulgin has stated that he doubts that 4-HO-DiPT could be distinguished from psilocin in any blinded clinical study. Due to its rapid onset and short duration among other qualities, 4-HO-DiPT has been described as a "good 'novice' introduction to hallucinogens".
File:Effects of luvesilocin at different doses on the Drug Effects Questionnaire over 6 hours.png|thumb|left|250px|class=skin-invert-image|Luvesilocin Drug Effects Questionnaire "feel high" ratings at doses of 5 to 40mg via subcutaneous injection over 6hours.
The effects of 4-HO-DiPT have been clinically studied in the form of its prodrug luvesilocin. Luvesilocin was evaluated at doses of 5 to 40mg by subcutaneous injection in this study. It was specifically assessed in terms of modified Drug Effects Questionnaire ratings, Mystical Experience Questionnaire ratings, and adverse effects.
Interactions
Pharmacology
Pharmacodynamics
4-HO-DiPT acts as an agonist of serotonin receptors, including the serotonin 5-HT2A and 5-HT2B receptors. It may also act as a serotonin reuptake inhibitor, although its potency is variable across studies. The drug appears to activate the serotonin 5-HT2C receptor with low potency and much lower than for the serotonin 5-HT2A receptor. However, in another study, it was only about 2.5-fold more potent as an agonist of the serotonin 5-HT2A receptor relative to the serotonin 5-HT2C receptor. The drug activates other serotonin receptors with lower potency as well. Unlike many other tryptamines, 4-HO-DiPT is not a ligand of the rodent trace amine-associated receptor 1.The drug has been found to produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In addition, it has fully efficacious anti-inflammatory effects in preclinical research. 4-HO-DiPT has also been found to produce anxiolytic effects in rodents.